Drug Trial Radar · NCT06887803
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Nov 17, 2025
Primary completion
Mar 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- iOncturaIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.
Conditions
- Myelofibrosis (MF)
Interventions
RoginolisibDrug
IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse eventsTime frame: Day 1 and 15 of cycle 1; Day 1 of each subsequent cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
- Number of Participants with abnormal ECG recordingsTime frame: Day 1 of each cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
- Number of participants with abnormal laboratory parametersTime frame: Day 1 and 15 of cycle 1; Day 1 of each subsequent cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
- Number of participants with changes in blood pressure measurementsTime frame: Day 1 and 15 of cycle 1; Day 1 of each subsequent cycle whilst on treatment anticipated to be 52 weeks. Cycle length 28 days
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Istituto di Ematolgia e Oncologia Medica
Bologna, Italy · Recruiting
Istituto Romagnolo per lo Studio dei Tumori
Meldola, Italy · Recruiting
Azienda Sanitario Universitaria Friuli Centrale
Udine, Italy · Recruiting
Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia
Florence, Florence, Italy · Recruiting
IRCCS Clinical Institute Humanitas
Rozzano, Milan, Italy · Recruiting
Vall d'Hebron University Hospital
Barcelona, Spain · Recruiting
Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
Barcelona, Spain · Recruiting
START Madrid CIOCC
Madrid, Spain · Recruiting
Hospital Universitario de Salamanca
Salamanca, Spain · Recruiting
Belfast City Hospital
Belfast, United Kingdom · Recruiting
Guy´s and St. Thomas NHS Foundation Trust
London, United Kingdom · Not yet recruiting
United Lincolnshire Teach Hospitals NHS Trust, Pilgrim Hospital Boston
Boston, Lincolnshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.